Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 01/09/2015
Chairman 71 15/04/2021
Director/Board Member 59 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 15.15L
+0.97%+1.61%-0.40%+28.12% 4.59TCr
-0.32%+4.61%+43.90%+26.98% 4.42TCr
-4.36%-5.66%+338.30%+516.88% 4.2TCr
+0.46%-0.83%+6.38%+73.76% 3.96TCr
-0.17%-3.22%+10.29%+38.69% 3.11TCr
-0.65%+5.14%+25.61%+120.17% 1.72TCr
+3.30%-5.03% - - 1.63TCr
+2.28%+7.78%+21.76%+38.93% 1.5TCr
+0.86%+9.05%+0.47%-33.54% 1.34TCr
Average +0.95%+1.18%+55.79%+101.25% 2.94TCr
Weighted average by Cap. +0.01%+0.31%+70.35%+122.83%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!